Latanoprost E Timololo Zentiva

Timolol maleate and Latanoprost, the active ingredients in Latanoprost E Timololo Zentiva, are a beta‑adrenergic antagonist and a prostaglandin F2α analog presented as an ophthalmic solution for ocular (topical) use. They lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension by reducing aqueous humor production and enhancing uveoscleral outflow.

GNH USA supplies Latanoprost E Timololo Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable global distribution and regulatory support.

Latanoprost E Timololo Zentiva is indicated for conditions affecting intra‑ocular pressure within the glaucoma and ocular hypertension disease family.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers elevated eye pressure to prevent progression to glaucoma. - Elevated intra‑ocular pressure: maintains target pressure levels to protect visual function.

The ophthalmic solution may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Blurred vision: transient visual disturbance after instillation. - Eye irritation: burning or stinging sensation. - Conjunctival hyperemia: redness of the eye. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual brownish pigmentation change. - Dry eye sensation: mild discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Ocular inflammation: uveitis or keratitis. - Significant reduction in heart rate: bradycardia. - Exacerbation of asthma: bronchospasm in susceptible patients. - Persistent visual loss: unexplained decrease in visual acuity.

Before prescribing Latanoprost E Timololo Zentiva, clinicians should consider several precautionary measures to ensure patient safety.

- Assess respiratory status: avoid in patients with asthma or severe chronic obstructive pulmonary disease. - Evaluate cardiac history: monitor for bradycardia or heart block in patients with cardiac conduction disorders. - Check ocular surface: discontinue if severe eye irritation or allergic reaction occurs. - Avoid concurrent beta‑blocker eye drops: may increase systemic beta‑blockade. - Inform patients about possible iris color change: irreversible pigmentation may develop. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost E Timololo Zentiva can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic beta‑blockers: additive bradycardia or hypotension. - Non‑selective beta‑adrenergic antagonists: increased risk of systemic beta‑blockade. - Other prostaglandin analog eye drops: excessive ocular effects.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce intra‑ocular pressure‑lowering effect. - Sympathomimetic agents (e.g., epinephrine): may counteract beta‑blocker action. - Anticholinergic eye drops: potential for reduced ocular surface tolerance.